Last reviewed · How we verify
EPAG-pfos
EPAG-pfos is a thrombopoietin receptor agonist that stimulates platelet production to treat thrombocytopenia.
EPAG-pfos is a thrombopoietin receptor agonist that stimulates platelet production to treat thrombocytopenia. Used for Immune thrombocytopenia (ITP), Chemotherapy-induced thrombocytopenia.
At a glance
| Generic name | EPAG-pfos |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Thrombopoietin receptor agonist |
| Target | TPO receptor (c-Mpl) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
EPAG-pfos activates the thrombopoietin (TPO) receptor on megakaryocyte progenitor cells, promoting their differentiation and maturation into megakaryocytes, which subsequently produce platelets. This mechanism increases circulating platelet counts in patients with low platelet levels due to various causes, including immune thrombocytopenia and chemotherapy-induced thrombocytopenia.
Approved indications
- Immune thrombocytopenia (ITP)
- Chemotherapy-induced thrombocytopenia
Common side effects
- Headache
- Fatigue
- Nausea
- Thrombotic events
Key clinical trials
- rhTPO Dose Escalation vs Eltrombopag Switch in ITP (NA)
- Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP (PHASE4)
- Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |